Bausch Health Companies Inc Asset Resilience Ratio
Bausch Health Companies Inc asset resilience ratio. Bausch Health Companies Inc (BHC) has an Asset Resilience Ratio of 4.97% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BHC days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Bausch Health Companies Inc (1999–2025)
Asset resilience ratio of Bausch Health Companies Inc from 1999 to 2025. This chart shows how Bausch Health Companies Inc's Asset Resilience Ratio has changed over time. Read Bausch Health Companies Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Bausch Health Companies Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Bausch Health Companies Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$1.31 Billion | 4.97% |
| Short-term Investments | CA$0.00 | 0% |
| Total Liquid Assets | CA$1.31 Billion | 4.97% |
Asset Resilience Insights
- Limited Liquidity: Bausch Health Companies Inc maintains only 4.97% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Bausch Health Companies Inc Industry Peers by Asset Resilience Ratio
Compare Bausch Health Companies Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Alembic Pharmaceuticals Limited
NSE:APLLTD |
Drug Manufacturers - Specialty & Generic | 0.14% |
|
Eris Lifesciences Limited
NSE:ERIS |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 9.44% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Bausch Health Companies Inc Asset Resilience Ratio by Year (1999–2025)
Bausch Health Companies Inc asset resilience ratio by year from 1999 to 2025. The table below shows the annual Asset Resilience Ratio data for Bausch Health Companies Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.97% | CA$1.31 Billion ≈ $946.91 Million |
CA$26.32 Billion ≈ $19.04 Billion |
+0.52pp |
| 2024-12-31 | 4.45% | CA$1.18 Billion ≈ $854.32 Million |
CA$26.52 Billion ≈ $19.19 Billion |
+0.99pp |
| 2023-12-31 | 3.46% | CA$947.00 Million ≈ $685.05 Million |
CA$27.35 Billion ≈ $19.78 Billion |
+1.27pp |
| 2022-12-31 | 2.20% | CA$564.00 Million ≈ $407.99 Million |
CA$25.69 Billion ≈ $18.58 Billion |
+0.20pp |
| 2021-12-31 | 1.99% | CA$582.00 Million ≈ $421.01 Million |
CA$29.20 Billion ≈ $21.12 Billion |
+0.05pp |
| 2020-12-31 | 1.94% | CA$605.00 Million ≈ $437.65 Million |
CA$31.20 Billion ≈ $22.57 Billion |
-7.64pp |
| 2019-12-31 | 9.58% | CA$3.24 Billion ≈ $2.35 Billion |
CA$33.86 Billion ≈ $24.50 Billion |
+6.95pp |
| 2018-12-31 | 2.63% | CA$721.00 Million ≈ $521.56 Million |
CA$27.45 Billion ≈ $19.85 Billion |
+0.71pp |
| 2017-12-31 | 1.92% | CA$720.00 Million ≈ $520.84 Million |
CA$37.50 Billion ≈ $27.12 Billion |
+0.67pp |
| 2016-12-31 | 1.25% | CA$543.00 Million ≈ $392.80 Million |
CA$43.53 Billion ≈ $31.49 Billion |
+1.21pp |
| 2015-12-31 | 0.03% | CA$16.00 Million ≈ $11.57 Million |
CA$48.96 Billion ≈ $35.42 Billion |
-0.13pp |
| 2014-12-31 | 0.16% | CA$43.00 Million ≈ $31.11 Million |
CA$26.35 Billion ≈ $19.06 Billion |
+0.07pp |
| 2013-12-31 | 0.09% | CA$25.20 Million ≈ $18.23 Million |
CA$27.97 Billion ≈ $20.23 Billion |
+0.07pp |
| 2012-12-31 | 0.02% | CA$4.41 Million ≈ $3.19 Million |
CA$17.95 Billion ≈ $12.99 Billion |
-0.02pp |
| 2011-12-31 | 0.05% | CA$6.34 Million ≈ $4.58 Million |
CA$13.14 Billion ≈ $9.51 Billion |
-0.01pp |
| 2010-12-31 | 0.06% | CA$6.08 Million ≈ $4.40 Million |
CA$10.80 Billion ≈ $7.81 Billion |
-0.41pp |
| 2009-12-31 | 0.46% | CA$9.57 Million ≈ $6.92 Million |
CA$2.07 Billion ≈ $1.50 Billion |
+0.40pp |
| 2008-12-31 | 0.06% | CA$997.00K ≈ $721.21K |
CA$1.62 Billion ≈ $1.17 Billion |
-0.16pp |
| 2007-12-31 | 0.22% | CA$3.90 Million ≈ $2.82 Million |
CA$1.78 Billion ≈ $1.29 Billion |
+0.20pp |
| 2005-12-31 | 0.02% | CA$511.00K ≈ $369.65K |
CA$2.19 Billion ≈ $1.58 Billion |
-0.23pp |
| 2004-12-31 | 0.25% | CA$5.02 Million ≈ $3.63 Million |
CA$2.01 Billion ≈ $1.46 Billion |
-10.13pp |
| 1999-12-31 | 10.38% | CA$65.90 Million ≈ $47.67 Million |
CA$635.10 Million ≈ $459.42 Million |
-- |
About Bausch Health Companies Inc
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmac… Read more